Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Decrease in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a large drop in short interest in October. As of October 30th, there was short interest totaling 22,618 shares, a drop of 85.8% from the October 15th total of 159,295 shares. Currently, 1.7% of the company’s stock are short sold. Based on an average daily volume of 48,253 shares, the short-interest ratio is presently 0.5 days.

Institutional Investors Weigh In On Enlivex Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ENLV. WINTON GROUP Ltd purchased a new stake in Enlivex Therapeutics during the second quarter worth approximately $55,000. Bank of America Corp DE boosted its holdings in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock valued at $121,000 after purchasing an additional 45,303 shares in the last quarter. Finally, Susquehanna International Group LLP boosted its holdings in Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock valued at $87,000 after purchasing an additional 147,334 shares in the last quarter. Institutional investors and hedge funds own 1.02% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Zacks Research cut Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Wall Street Zen upgraded shares of Enlivex Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 29th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Enlivex Therapeutics in a report on Tuesday, September 22nd. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Enlivex Therapeutics presently has an average rating of “Hold” and an average price target of $4,800.00.

Enlivex Therapeutics Stock Performance

NASDAQ ENLV traded up $0.01 during trading on Wednesday, reaching $1.21. 17,022 shares of the company’s stock were exchanged, compared to its average volume of 24,488. The stock has a market cap of $1.84 million, a P/E ratio of -0.01 and a beta of 1.63. The company has a 50 day moving average price of $7.51 and a two-hundred day moving average price of $131.49. Enlivex Therapeutics has a 1 year low of $1.20 and a 1 year high of $434.40.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) is an Israel-based clinical-stage biotechnology company developing cell-based immunotherapies designed to restore balance to dysregulated immune responses. The company’s approach is intended to address conditions in which excessive or uncontrolled inflammation contributes to disease progression. Enlivex’s lead product candidate is Allocetra-OTS, an off-the-shelf cell therapy made from apoptotic cells. The therapy is designed to reprogram the immune system toward a balanced state by helping regulate the activity of immune cells, including macrophages.